


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	FORODESINE
PRONUNCIATION	fore' oh de seen
THERAPEUTIC CLAIM	Treatment of T-Cell malignancies such as acute lymphoblastic leukemia (ALL) and cutaneous T-cell lymphoma (CTCL)

CHEMICAL NAMES

- 1) 4*H*-Pyrrolo[3,2-*d*]pyrimidin-4-one, 7-[(2*S*,3*S*,4*R*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-1,5-dihydro-
- 2) (-)-7-[(2*S*,3*S*,4*R*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₁₁ H ₁₄ N ₄ O ₄
MOLECULAR WEIGHT	266.26
TRADEMARK	Fodosine™
MANUFACTURER	BioCryst Pharmaceuticals
CODE DESIGNATION	BCX-1777
<u>CAS</u> REGISTRY NUMBER	209799-67-7